Encaleret

AssetAlso CLTX-305, Encaleret Sulfate, JTT-305

Negative allosteric modulator (calcilytic) of the calcium-sensing receptor.

Stage: Phase 3
Modality: Small molecule
Target: Not known; 1
Indication: 1
Trial: 1
Developer

Indications

1

Autosomal dominant hypocalcemia
Phase 3, Active not recruiting, NCT05680818, clinicaltrials.gov, Oct 31, 2026

In the full profile

Owner and partners1
Trials1
Competitors1
Signals2

Every asset’s record: target, stage, trials and the evidence behind it.